Drug Discovery Partnerships
Collaborating to achieve cutting-edge breakthroughs
As well as progressing its own drug discovery programmes, Beactica enters into partnerships selectively with other companies and world-leading drug discovery centres. This provides an efficient and flexible way to leverage the power of Beactica's drug discovery platform and build additional value for the Company.
The collaboration with Dong-A ST started in October 2016. The aim of the partnership is to jointly develop novel anti-cancer drugs against certain disease-related oncology targets.
Under the terms of the agreement, Dong-A ST gained exclusive global rights for the further development and commercialization of Beactica’s small molecule inhibitors against multiple members of a family of epigenetic enzymes. The partnership pools existing compound series from both companies and combines Beactica's unique early-stage lead generation capabilities with DONG-A ST's strengths in downstream pre-clinical and clinical development of new therapeutic agents.
Beactica received an undisclosed upfront payment and research funding and is eligible to receive potential milestone payments for certain research, preclinical, clinical and regulatory milestones. In addition, Dong-A will pay royalties on commercial sales of any marketed products resulting from the partnership. Beactica is also entitled to a revenue share from any related future licensing activities by Dong-A ST.
The collaboration with VIB and KU Leuven’s Centre for Drug Design and Discovery (CD3) was announced in March 2019. The aim of the partnership is to generate new leads against an innovative target for a range of inflammatory conditions.
The collaboration will leverage core capabilities of each partner and builds on the work of Prof. Dr Savvas Savvides (VIB-UGent), whose major research focus concerns macromolecular signalling complexes pivotal to inflammation. The alliance will use Beactica’s proprietary drug discovery platform that enables the identification of novel small molecule modulators against challenging target proteins. CD3’s drug discovery capabilities, including its medicinal chemistry resources and expertise, will be driving the optimisation of small molecule modulators towards new medicines. VIB Discovery Sciences will focus on the translational research needed to deliver validated candidates for small molecule therapeutics. The terms of the collaboration have not been disclosed.
The press release about the partnership with VIB and CD3 can be found here.